好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Knowledge and Attitudes about Epilepsy in a Low Socioeconomic Population
Epilepsy
P03 - (-)
124
BACKGROUND: The prevalence of epilepsy in the United States is 2 million, and about 50 million worldwide. Studies have shown a higher incidence and prevalence in people of low socioeconomic status (SES). Misconceptions regarding epilepsy and medication non-compliance are more common in patients of low SES and in racial and ethnic minorities. Prior studies have assessed patients' knowledge about epilepsy using the Epilepsy Knowledge Profile-Personal (EKP-P) scale. We used this scale at the Ben Taub General Hospital, Houston, TX, with a goal to set up a formal epilepsy educational program.
DESIGN/METHODS: The study is a cross sectional survey. Informed consent was obtained and 150 subjects have been enrolled. The pre-test questionnaire (EKP-P) to determine baseline knowledge of epilepsy has been completed. Subjects are now attending epilepsy education classes to complete post-test questionnaires.
RESULTS: 54% of the population was male, with an average age of 37.8 years. Majority of subjects were Hispanic (43.3%) or African American (32%), followed by Caucasians (20.7%), and Asians and other ethnicities (<5%). 71% had an education level of high school or less. 61% had an annual income of less than $10,000. The mean duration of epilepsy was 16.4 years. Based on the pretest questionnaire, 51% of patients felt they did not know enough about epilepsy and 16% did not accept their diagnosis. 40% of patients were unaware of safety precautions for epilepsy. 12 % did not know the names or doses of their medications. More than 50% were not aware of their diagnostic work up.
CONCLUSIONS: Low SES is a determinant of epilepsy knowledge and medication compliance. Formal patient education modules focusing on disease description, medication management and safety precautions may help improve compliance and seizure management in this population.
Authors/Disclosures
Sahar Zafar, MD
PRESENTER 		Dr. Zafar has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Zafar has received research support from NIH. Dr. Zafar has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker for a lecture with Marinus.
Emily C. Iannopollo, MD (Barnes Jewish Hospital) No disclosure on file
Saumya Gill, MD (Novant Health UVA Health System) No disclosure on file
David E. Friedman, MD (Winthrop University Hospital) No disclosure on file
James M. Meyer, PharmD (Marathon Pharmaceuticals, LLC) No disclosure on file
Joseph S. Kass, MD, JD, FAAN (Baylor College of Medicine) Dr. Kass has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生 . Dr. Kass has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Kass has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Multiple Law Firms . Dr. Kass has received publishing royalties from a publication relating to health care.
Corey Goldsmith, MD, FAAN (Baylor College of Medicine - Department of Neurology) Dr. Goldsmith has received publishing royalties from a publication relating to health care.